UsAgainstAlzheimer’s Statement on Disappointing Results from DIAN-TU Clinical Trial

Washington, D.C. (February 10, 2020) – UsAgainstAlzheimer’s today released the following statement regarding the negative results of anti-amyloid Alzheimer's drug therapies of Eli Lilly and of Roche and its U.S. affiliate Genetech. The companies said today that topline results from a DIAN-TU Phase II/III study involving patients with a rare inherited form of the disease showed that Lilly’s solanezumab and Roche/Genetech’s gantenerumab did not meet their primary endpoint of slowing memory loss and cognitive decline.

“These results are the latest reminder that the road to effective Alzheimer’s treatments is filled with disappointment for patients, caregivers, companies and researchers. But disappointments like this must be met with a continued commitment from industry and policymakers to invest in strategies to treat, prevent, and ultimately cure Alzheimer's.

“There have been other promising signs of hope in the development of Alzheimer’s drug therapies, proving that the investment in research is paying off. While the DIAN results are not what we were hoping for, we know that the study results and analyses will deepen our understanding of Alzheimer’s and move us closer to a cure.

“We are grateful to the patients who took part in the DIAN-TU clinical trials and share their disappointment. Like them, we know that the first person cured of Alzheimer's will be enrolled in a clinical trial. We applaud Roche, Lilly and other companies for their investment in Alzheimer's. For the tens of millions American families touched by this disease, the fight must continue in order to reach the national goal of achieving an effective treatment for Alzheimer’s by 2025.”


About UsAgainstAlzheimer’s (UsA2)

UsAgainstAlzheimer’s (UsA2) is a disruptive advocacy and research-focused organization that is pushing for expanding treatments and accelerating towards a cure for Alzheimer’s disease. UsA2’s transformative programming is laser-focused on proactive brain health across the lifespan and understanding what matters most across the lived experiences of those affected by Alzheimer’s in the service of preventing, treating and curing this disease.  We are working to ensure that all communities have their voices heard, and get a chance to be brain healthy from the earliest years while building resistance to and resilience against possible cognitive decline.